Our consultants

Marie Fallon is the St Columba’s Hospice Chair of Palliative Medicine at the University of Edinburgh and an Honorary Consultant in Palliative Care at the Western General Hospital in Edinburgh, Scotland. She leads a large portfolio of multicentre clinical trials in Palliative Care of which three are CRUK-funded.

She has developed the group from her single appointment to the Chair in 2006. In addition, to the largest portfolio of clinical trials in Palliative Care in the United Kingdom, she has developed an International PhD programme with the University of Trondheim, Norway.

Professor Fallon is a joint editor of the Oxford Textbook of Palliative Medicine (4th and 5th editions) and has served as editor of the ABC of Palliative Care (two editions) the ABC of Pain and the Textbook of Cancer Pain. She is a member of the Advisory Board for Dimbleby Cancer Care, and the joint Dimbleby Cancer Care/Marie Curie Cancer Care Research Fund and is chair of the Cancer Pain Sub Group of the NCRI Palliative Care Clinical Studies Group. She is a Collaborating Centre Lead for the European Palliative Care Research Centre, which is based in Trondheim. She is also a Visiting Professor for the European Palliative Care Research Centre.

Marie Fallon has embedded clinical biomarkers in her research programme with the aim of moving towards efficient identification of the most appropriate treatments.

Dr Neill Storar is a Consultant Haematologist at the Centre.

Dr Sundaramurthy is a consultant clinical oncologist specialising in prostate and bladder malignancies and the clinical lead for radiotherapy services at the ECC.

After completing his specialist training in clinical oncology at the Edinburgh cancer centre, he did a clinical research fellowship at the Princess Margaret cancer centre and University of Toronto, further sub-specialising in genitourinary malignancies, advanced prostate radiotherapy and brachytherapy. During his fellowship, he was awarded the CARO-ACURA 2017 grant towards phase 2 study as principal investigator, for combining MRI-guided HDR brachytherapy with Stereotactic Body Radiotherapy (SABR) for Prostate Cancer.

He returned back from Toronto to take the role of consultant in clinical oncology at the Edinburgh cancer Centre in 2017. Here, he successfully led the case for implementing HDR-brachytherapy for prostate cancers. The first Scottish patient was treated in April 2021. He also does real-time planned LDR-brachytherapy for prostate cancers.

He is also a member of the SABR (or SBRT) group at the Edinburgh cancer centre for oligometastatic cancers. He does spine, bone and lymph node SBRT for all oligometastatic malignancies. He was awarded the RCR-Kay visiting fellowship 2019 learn new techniques in radiation oncology.

As a lead for team 4 trials (Genitourinary cancers) at the ECC, he manages the trials team and is a principal investigator for a number of successfully running trials. He was appointed clinical lead for radiotherapy services in 2024.

Professor Peter Hall is an academic Medical Oncologist with a research interest in Health Economics, Data Science and Health Technology Assessment in Cancer. He treats patients with breast cancer within the NHS at the Edinburgh Cancer Centre. The focus of his research is on the development of improved methods for efficient research design, cost-effectiveness analysis and the measurement of clinical and socioeconomic outcomes using data obtained from clinical trials and routinely collected within health systems.

He has contributed to the design of a series of pragmatic clinical trials in the UK that aim to address questions that are important to real-world patients with cancer treated by the NHS. Examples include the PETNECK, 321GO, GO2, PERSEPHONE, OPTIMA and MAMMO-50 trials.

He graduated from the University of Edinburgh Medical School in 2003, undertaking general medical training in Fife and Dundee. He commenced specialist training in Medical Oncology with the Yorkshire Deanery in 2006. He undertook a NICE scholarship in 2007. He completed a PhD in Health Economics and Clinical Trial design at the University of Leeds in 2012. In 2014 he took up his current position in Edinburgh.

He leads the Edinburgh Health Economics Group within the University of Edinburgh Clinical Trials Unit. He has been a NICE Appraisal Committee member 2017-2020. He is a Visiting Associate Professor of Health Economics at the Academic Unit of Health Economics, University of Leeds . He also runs the Cancer Informatics Programme at the Edinburgh Cancer Centre

Prof. Cameron’s first degree was in mathematics from the University of Cambridge, and he received his medical degree in 1986 from St. George’s Hospital Medical School, London. After completing a fellowship and MSc in Clinical Oncology at the University of Edinburgh, he received a M.D. with distinction in 1997 and completed his training as a medical oncologist that same year. He is currently Professor of Oncology at Edinburgh University, and works in NHS Lothian’s cancer centre treating breast cancer patients, and is the joint lead for the Edinburgh Experimental Cancer Medicine Centre. He is currently also the part/time deputy director role within the Scottish Government funded Innovative Health Care Delivery Programme (IHDP) which seeks to improve on access to, and enhance the use of, routine data on cancer patients within NHS Scotland. He also chairs the Scottish Cancer SACT data group, off label cancer medicines’ group and is Scottish Government R&D (CSO) clinical cancer research champion.

Internationally he is the chair of the Breast International Group, a Brussels-based umbrella group of 57 worldwide academic/not-for-profit breast cancer trials’ groups, and the vice chair of the steering group of the Oxford-based Early Breast Cancer Clinical Trialists’ Group. He is active in a number of current and past clinical trials in breast cancer.

Between November 2006 & June 2010 he was Director of the NIHR-funded National Cancer Research Networks, and at the end of 2009 took up a new post as Professor of Oncology at Edinburgh University and Director of Cancer Services in NHS Lothian. He was a member of the executive committee of the HERA adjuvant herceptin trial, and a member of the steering group for several UK adjuvant breast cancer trials, as well as the BIG APHINITY, ALTTO/NEO_ALTTO, BRAVO and AURORA studies and other international breast cancer studies. He was chief investigator on the UK trial adjuvant breast cancer trial, TACT2, and of BEATRICE, a global trial that tested the possible benefit of adjuvant bevacizumab in triple negative breast cancer, and serves on the iDMC of a number of clinical trials in breast and other cancers. He is at present and past member of several cancer research funding committees including INCA PHRC, PAIR (Sein), Cancer Research UK Science committee, Cancer Research UK Clinical Research Committee, and from time to time various NIHR funding bodies including EME, clinical trials fellows committee. He is on the advisory board of the ICR and Glasgow Clinical Trials Units, the Bordeaux Institute Bergonie SIRIC and the Cardiff Cancer Clinical and Translational Research programme.

Dr Michie is a consultant medical oncologist, honorary clinical senior lecturer and NRS research clinician at the Edinburgh Cancer Centre & University of Edinburgh. She is principal investigator on several clinical trials in breast cancer and UK chief investigator for the DESTINY BREAST-09 study. She is currently the lead clinician for the Edinburgh breast cancer clinical trial team and the Lead Clinician for Systemic Anti Cancer Therapy (SACT) for NHS Fife.

As lead clinician for the trials team, she oversees the trial portfolio and is the first port of call for potential collaboration for clinical trials in breast cancer with industry or investigator-led studies. The portfolio aims to have studies available for all the main breast cancer subtypes in both the curative and metastatic settings, aiming to be able to offer clinical trial access to as many patients with breast cancer as possible. Edinburgh was selected by Astra Zeneca as one of their preferred UK sites for clinical trial collaboration in 2022 and was the lead UK or Europe recruiter for several studies over recent years. The trial team comprises 4-5 dedicated research nurses and 5 data managers, in addition to 7 medical oncology and 5 clinical oncology investigators. There are also regional clinical trial teams in Fife, St Johns, Borders General Hospital and Dumfries and Galloway Royal Infirmary.

Dr Killean specialises in the treatment of genito-urinary cancers, principally prostate and bladder cancer. He graduated from the University of Edinburgh and completed post-graduate training NHS Tayside and NHS Lothian. This included two years of clinical research, completing a medical doctorate in the topic of cell-free DNA and radiotherapy. He has continued involvement in clinical research and service development.

Mr Young was an undergraduate in Edinburgh. He undertook the majority of his basic surgical training on the South East of Scotland rotation. This was followed by full-time laboratory research in the University of Edinburgh Department of Pathology, Molecular Medicine Centre, Western General Hospital, Edinburgh.He then moved to higher surgical training in the West of Scotland as a clinical lecturer in surgery, University of Glasgow.He was appointed as a consultant in breast surgery in 2005.